In a post on LinkedIn, Lotte Bjerre Knudsen announced her departure. She has held the role of Chief Scientific Advisor and has been central to the development of the company’s GLP-1-based treatments.
“I grew up at Novo Nordisk and have spent my professional life here until now – working with fantastic scientists, colleagues, friends, leaders, partners, and many other collaborators outside the company,” she writes in the post.
BREAKING